128 related articles for article (PubMed ID: 9088956)
1. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma.
Attanoos RL; Webb R; Gibbs AR
Histopathology; 1997 Mar; 30(3):260-3. PubMed ID: 9088956
[TBL] [Abstract][Full Text] [Related]
2. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
3. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium.
Sato A; Torii I; Okamura Y; Yamamoto T; Nishigami T; Kataoka TR; Song M; Hasegawa S; Nakano T; Kamei T; Tsujimura T
Mod Pathol; 2010 Nov; 23(11):1458-66. PubMed ID: 20657552
[TBL] [Abstract][Full Text] [Related]
4. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
Ordóñez NG
Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
[TBL] [Abstract][Full Text] [Related]
5. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
6. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma.
Attanoos RL; Goddard H; Gibbs AR
Histopathology; 1996 Sep; 29(3):209-15. PubMed ID: 8884348
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
Roberts F; Harper CM; Downie I; Burnett RA
Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073
[TBL] [Abstract][Full Text] [Related]
8. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
9. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
Sheibani K; Battifora H; Burke JS
Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
[TBL] [Abstract][Full Text] [Related]
10. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
Attanoos RL; Griffin A; Gibbs AR
Histopathology; 2003 Sep; 43(3):231-8. PubMed ID: 12940775
[TBL] [Abstract][Full Text] [Related]
11. Expression of blood group-related antigens and Helix pomatia agglutinin in malignant pleural mesothelioma and pulmonary adenocarcinoma.
Kawai T; Suzuki M; Torikata C; Suzuki Y
Hum Pathol; 1991 Feb; 22(2):118-24. PubMed ID: 2001875
[TBL] [Abstract][Full Text] [Related]
12. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.
Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG
Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases.
Otis CN; Carter D; Cole S; Battifora H
Am J Surg Pathol; 1987 Jun; 11(6):445-56. PubMed ID: 2438954
[TBL] [Abstract][Full Text] [Related]
14. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
15. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
Kawai T; Greenberg SD; Truong LD; Mattioli CA; Klima M; Titus JL
Am J Pathol; 1988 Feb; 130(2):401-10. PubMed ID: 2449084
[TBL] [Abstract][Full Text] [Related]
16. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
Klebe S; Swalling A; Jonavicius L; Henderson DW
J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
[TBL] [Abstract][Full Text] [Related]
17. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
Dejmek A; Hjerpe A
Cytopathology; 2000 Feb; 11(1):8-17. PubMed ID: 10714371
[TBL] [Abstract][Full Text] [Related]
18. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
Brown RW; Clark GM; Tandon AK; Allred DC
Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
[TBL] [Abstract][Full Text] [Related]
19. High CD44 expression on human mesotheliomas mediates association with hyaluronan.
Penno MB; Askin FB; Ma H; Carbone M; Vargas MP; Pass HI
Cancer J Sci Am; 1995; 1(3):196-203. PubMed ID: 9166476
[TBL] [Abstract][Full Text] [Related]
20. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]